- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00031850
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
A Randomized Trial Of Raloxifene Plus Zoladex For Prevention Of Breast Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene and goserelin may be effective in preventing breast cancer.
PURPOSE: Randomized pilot study to study the effectiveness of combining raloxifene and goserelin in preventing breast cancer in women who have a family history of breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Compare the feasibility of raloxifene and goserelin versus no medical intervention in women at high genetic risk for developing breast cancer.
- Compare the incidence of adverse effects in patients treated with these regimens.
- Compare the effect of these regimens on bone density, biochemical markers of bone turnover, and lipid profiles in these patients.
- Compare the quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive goserelin subcutaneously once every month and oral raloxifene daily for 6-12 months.
- Arm II: Patients are screened for breast cancer every 6 months. In both arms, patients undergo annual mammograms.
Quality of life is assessed at baseline and at 1, 3, 6, and 12 months.
Patients are followed for 5 years.
PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
England
-
Manchester, England, United Kingdom, M20 4BX
- Christie Hospital NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
High genetic risk of developing breast cancer defined as one or more of the following:
- BRCA1 or BRCA2 germ-line mutation
- First-degree relative of known BRCA1 or BRCA2 mutation carrier
- Family with 4 or more relatives diagnosed with female or male breast cancer or ovarian cancer before the age of 60
- Two first-degree relatives diagnosed with breast cancer before the age of 40
- p53 germ-line mutation (classical Li-Fraumeni syndrome (LFS) only)
- First-degree relative of a carrier in a family with classical LFS
- Risk equivalent to any of the above confirmed by clinical geneticist
No evidence of breast cancer by mammography
- Suspicious lesions must be confirmed as non-malignant
- No prior breast cancer
- No prior prophylactic mastectomy
- No plan for alternative prevention measures within the next 12 months
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 30 to 45
Sex:
- Female
Menopausal status:
- Premenopausal (follicle-stimulating hormone in premenopausal range if not menstruating)
Performance status:
- Not specified
Life expectancy:
- More than 10 years (excluding breast cancer risk)
Hematopoietic:
- Not specified
Hepatic:
- Adequate liver function
Renal:
- Adequate renal function
Cardiovascular:
- No prior deep vein thrombosis
Pulmonary:
- No prior pulmonary embolism
Other:
- Not pregnant
- Fertile patients must use effective nonhormonal contraception
- No psychological disorder that would preclude study compliance
- No prior malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or cervical cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- No concurrent hormonal therapy (e.g., oral contraception or hormone replacement therapy)
Radiotherapy:
- Not specified
Surgery:
- See Disease Characteristics
Other:
- At least 30 days or 5 half-lives since prior investigational drugs
- No concurrent anticoagulants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Goserelin
- Raloxifene Hydrochloride
Other Study ID Numbers
- NCRI-IBIS-RAZOR
- CDR0000069233 (Registry Identifier: PDQ (Physician Data Query))
- EU-20053
- UKCCCR-IBIS-RAZOR
- ISRCTN17775670
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on goserelin acetate
-
CMX ResearchPeptigroupe Inc.CompletedProstate CancerCanada, Georgia
-
Eurofarma Laboratorios S.A.Recruiting
-
Peking University People's HospitalUnknownInfertility Associated With Endometriosis
-
Luye Pharma Group Ltd.Completed
-
AstraZenecaWithdrawn
-
AstraZenecaCompletedAdvanced Breast CancerRussian Federation, Ukraine, Czech Republic
-
Luye Pharma Group Ltd.CompletedProstate CancerChina
-
Luye Pharma Group Ltd.Completed
-
424 General Military HospitalAristotle University Of Thessaloniki; 251 Hellenic Air Force & VA General HospitalCompletedEndometriosis | Bone Density | Muscle | Bone MetabolismGreece
-
AstraZenecaCompleted